Neuberger Berman Group
GILD icon

Neuberger Berman Group’s Gilead Sciences GILD Stock Holding History

Neuberger Berman Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,843
Closed -$1.21M – 1558
2020
Q1 		$1.21M Buy
+1,843
New +$127K ﹤0.01% 1055

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group's GILD Position: Q1 2026 in Review

Neuberger Berman Group reduced its Gilead Sciences (GILD) stake by 2.1% in Q1 2026, selling an estimated $3.98M and leaving 1,331,058 shares worth $186M. The position accounts for 0.14% of the portfolio, ranked #161.

Neuberger Berman Group first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $451M in Q4 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Neuberger Berman Group held 1,331,058 shares of Gilead Sciences worth $186M as of Q1 2026.
  • Neuberger Berman Group sold 28,386 Gilead Sciences shares in Q1 2026, an estimated $3.98M.
  • Gilead Sciences made up 0.14% of Neuberger Berman Group's portfolio in Q1 2026, its #161 holding.
  • Neuberger Berman Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Neuberger Berman Group's Gilead Sciences position peaked at $451M in Q4 2023.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.